Table 3.
Treatment-emergent AEs that occurred in ≥2% of galcanezumab-treated patients treated with either dose of galcanezumab and greater than placebo
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.